Site icon Snackfax

D2C platform The Ayurveda Experience achieves remarkable revenue growth in FY23, sets course for profitability

tae

TAE inaugurated its inaugural standalone brand store in the US in October 2022 and intends to open an additional store this quarter.

The Ayurveda Experience (TAE), a direct-to-consumer (D2C) platform that sells products across 20+ countries, is poised to achieve profitability in the current fiscal year after experiencing strong growth in FY23. The health and wellness startup saw a noteworthy 91.48% increase in revenue, reaching INR 270 crore in FY22-23, up from INR 141 crore in FY21-22.

TAE has received support from well-known investors such as Anicut Capital, Fireside Ventures, The Kalpavriksh Fund (Centrum Group), Sharrp Ventures (Mariwala Family Office), Riverwalk Ventures, Singularity Ventures, Emerge Capital, and more.

Rishabh Chopra, Founder & CEO, TAE, said, “This growth in revenue over the years can be mainly attributed to launching new products that help solve user concerns, rampant growth in our European markets, and significant optimisations in our advertising cost-to-revenue ratio and promotion costs as a ratio of revenue.”

“We expect to be profitable in the current FY 2023-24. We were already profitable in the USA and Canada in FY23,” he added.

TAE was founded in 2010 and has established an Ayurveda-focused D2C platform to serve customers in North America, Europe, Australia, and India. Its product range spans across categories like skincare, body care, personal care, and supplements. The company has raised INR 105 crore in primary capital and attracted around INR 30 crore through secondary share purchases from investors.

“North America is our biggest market but we have seen rapid adoption of Ayurveda products in European markets in recent times,” Chopra said.

TAE inaugurated its inaugural standalone brand store in the US in October 2022 and intends to open an additional store this quarter.

Talking about future investment plans Chopra said, “We are actively investing in new product development/research. enhancement of existing products and scientific/ clinical trials. We are also investing in supply chain technologies, and technologies to help recommend products better to our users/personalize the purchase experience for our users.”

Exit mobile version